Neumann-Haefelin D
Fortschr Med. 1977 Apr 28;95(16):1093-4.
Human leukocyte interferon (HLI) was used for treatment of human diploid fibroblasts before and after infection with vaccinia virus, herpes simplex virus type 1 (HSV 1), herpes simplex virus type 2 (HSV 2), and varicella zoster virus (VZV). Vero cells were infected with Medical Lake macaque herpes virus (MLMV), and treated with HLI in the same way. In all of these systems HLI exhibited an antiviral effect when administered before infection, and this effect could be increased by additional HLI treatment after infection. In vivo studies with HLI treatment were performed in monkeys experimentally infected with vaccinia virus, HSV 1, and MLMV. Vaccinia and herpes keratitis were prevented by local, prophylactic administration of HLI. Generalized infections with vaccinia virus and MLMV in monkeys immunosuppressed by antilymphocyte globulin, were significantly modified by either prophylactic or therapeutic systemic treatment with HLI.
人白细胞干扰素(HLI)用于在人二倍体成纤维细胞感染痘苗病毒、单纯疱疹病毒1型(HSV 1)、单纯疱疹病毒2型(HSV 2)和水痘带状疱疹病毒(VZV)之前及之后进行治疗。将非洲绿猴肾细胞(Vero细胞)感染麦克尼尔湖猕猴疱疹病毒(MLMV),并以相同方式用HLI进行处理。在所有这些系统中,HLI在感染前给药时表现出抗病毒作用,并且在感染后额外给予HLI处理可增强这种作用。用HLI治疗的体内研究在实验感染痘苗病毒、HSV 1和MLMV的猴子中进行。通过局部预防性给予HLI可预防痘苗性角膜炎和疱疹性角膜炎。在用抗淋巴细胞球蛋白免疫抑制的猴子中,痘苗病毒和MLMV的全身性感染通过HLI的预防性或治疗性全身治疗得到显著改善。